DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zioptan (Tafluprost) - Summary



Tafluprost is a fluorinated analog of prostaglandin F2-alpha.

ZIOPTAN™ (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

See all Zioptan indications & dosage >>


Published Studies Related to Zioptan (Tafluprost)

[Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study]. [Article in Japanese] [2010]
CONCLUSION: These results indicate that Tafluprost is clinically useful in the

Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. [2010]
open-angle glaucoma or ocular hypertension... CONCLUSIONS: Tafluprost is a new effective and well-tolerated treatment for

A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost. [2010]
exfoliation glaucoma, or ocular hypertension... CONCLUSIONS: Tafluprost and latanoprost have comparable effects on the extent,

Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. [2009]
hypertension, uncontrolled by timolol monotherapy... CONCLUSIONS: As adjunctive therapy to timolol, tafluprost achieved a consistently

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. [2008]
analogue with a preservative-free formulation... CONCLUSIONS: THE reduction in IOP achieved by preservative-free tafluprost is

more studies >>

Clinical Trials Related to Zioptan (Tafluprost)

Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP) [Completed]

- Main objective is to compare the ability of Latanoprost 0. 005% preservative-added

ophthalmic solution versus Tafluprost 0. 0015% preservative-free ophthalmic solution, both given once a day at the evening, in reducing 24-hour intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) and/or ocular hypertension (OHT) at first diagnosis. First efficacy variable will be the difference between mean nocturnal IOP values after three months of treatment: nocturnal IOP is defined as the mean value between 2AM and 6AM measurements.

- Secondary objectives will be the comparison between Latanoprost 0. 005% and Tafluprost

0. 0015% ophthalmic solution about:

- Mean 24-hour IOP values after three months of treatment

- IOP values at these time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour),

10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment

Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops [Completed]

Tafluprost-Timolol Fixed Dose Combination Non-Inferiority Study Against Concomitant Administrations [Completed]
The purpose of this study is to compare the efficacy and safety of the preservative-free fixed-dose combination of tafluprost and timolol (FDC) to concomitant administration of tafluprost and timolol. This study will enroll patients who have ocular hypertension or glaucoma. The study schedule includes seven visits to the study site and three stages:

- washout of 5 days to 4 weeks depending on current glaucoma medication (if any)

- 6-month study treatment period

- 1-3 weeks post-study period

An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More [Completed]
Increased intraocular pressure (IOP) has been identified as the most important risk factor for the development and the progression of glaucoma. Data from large interventional studies have shown that a decrease of IOP is associated with a reduced risk of progression of the disease. This underlines the importance of a potent and save IOP lowering therapy. The introduction of preservative free tafluprost offers a new treatment possibility using a potent topical prostaglandin analogue without the disadvantages of a co-administered preservative. The current study seeks to investigate the effect of an 8 week therapy with preservative free tafluprost on intraocular pressure in patients with ocular hypertension or primary open angle glaucoma having an IOP of 30 mmHg or more.

The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma [Completed]
The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0. 005% eye drops (Xalatan) and after the switch to preservative-free prostaglandin analog tafluprost 0. 0015% eye drops (Taflotan®). Patients who have been using latanoprost as their prior medication (at least 6 months) and who fulfil all the inclusion criteria including the specified ocular symptoms and signs, will switch from latanoprost 0. 005% eye drops to the assigned preservative-free tafluprost 0. 0015% eye drops for twelve (12) months.

more trials >>

Reports of Suspected Zioptan (Tafluprost) Side Effects

Ocular Hyperaemia (8)Drug Ineffective (4)Eye Irritation (4)Growth of Eyelashes (4)Cough (4)Eye Pruritus (4)Eye Pain (4)Nasopharyngitis (3)Headache (3)Urinary Tract Infection (3)more >>

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017